Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Jun;33(6):791–796. doi: 10.1128/aac.33.6.791

Vancomycin- and erythromycin-induced hearing loss in humans.

R E Brummett 1, K E Fox 1
PMCID: PMC284231  PMID: 2669623

Full text

PDF
791

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad R., Raichura N., Kilbane V., Whitfield E. Vancomycin: a reappraisal. Br Med J (Clin Res Ed) 1982 Jun 26;284(6333):1953–1954. doi: 10.1136/bmj.284.6333.1953-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beckner R. R., Gantz N., Hughes J. P., Farricy J. P. Ototoxicity of erythromycin gluceptate. Am J Obstet Gynecol. 1981 Mar 15;139(6):738–739. doi: 10.1016/0002-9378(81)90501-9. [DOI] [PubMed] [Google Scholar]
  3. Brummett R. E., Bendrick T., Himes D. Comparative ototoxicity of bumetanide and furosemide when used in combination with kanamycin. J Clin Pharmacol. 1981 Nov-Dec;21(11-12):628–636. doi: 10.1002/j.1552-4604.1981.tb05675.x. [DOI] [PubMed] [Google Scholar]
  4. Brummett R. E., Brown R. T., Himes D. L. Quantitative relationships of the ototoxic interaction of kanamycin and ethacrynic acid. Arch Otolaryngol. 1979 May;105(5):240–246. doi: 10.1001/archotol.1979.00790170010003. [DOI] [PubMed] [Google Scholar]
  5. Brummett R. E. Ototoxicity resulting from the combined administration of potent diuretics and other agents. Scand Audiol Suppl. 1981;14 (Suppl):215–224. [PubMed] [Google Scholar]
  6. Cohen I. J., Weitz R. Psychiatric complications with erythromycin. Drug Intell Clin Pharm. 1981 May;15(5):388–388. [PubMed] [Google Scholar]
  7. Cook F. V., Farrar W. E., Jr Vancomycin revisited. Ann Intern Med. 1978 Jun;88(6):813–818. doi: 10.7326/0003-4819-88-6-813. [DOI] [PubMed] [Google Scholar]
  8. DUTTON A. A., ELMES P. C. Vancomycin: report on treatment of patients with severe staphylococcal infections. Br Med J. 1959 May 2;1(5130):1144–1149. doi: 10.1136/bmj.1.5130.1144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Davis R. R., Brummett R. E., Bendrick T. W., Himes D. L. The ototoxic interaction of viomycin, capreomycin and polymyxin B with ethacrynic acid. Acta Otolaryngol. 1982;93(1-6):211–217. doi: 10.3109/00016488209130874. [DOI] [PubMed] [Google Scholar]
  10. Demaldent J. E., Rolland A., Mongrolle Y. Potentiel ototoxique de l'érythromycine. Ann Otolaryngol Chir Cervicofac. 1984;101(8):643–647. [PubMed] [Google Scholar]
  11. Dylewski J. Irreversible sensorineural hearing loss due to erythromycin. CMAJ. 1988 Aug 1;139(3):230–231. [PMC free article] [PubMed] [Google Scholar]
  12. Eckman M. R., Johnson T., Riess R. Letter: Partial deafness after erythromycin. N Engl J Med. 1975 Mar 20;292(12):649–649. [PubMed] [Google Scholar]
  13. Errick J. K., Hyrciuk-Flaska L., Thies H. Correction to erythromycin ototoxicity. Drug Intell Clin Pharm. 1981 Feb;15(2):133–133. doi: 10.1177/106002808101500217. [DOI] [PubMed] [Google Scholar]
  14. Esposito A. L., Gleckman R. A. Vancomycin. A second look. JAMA. 1977 Oct 17;238(16):1756–1757. doi: 10.1001/jama.238.16.1756. [DOI] [PubMed] [Google Scholar]
  15. Farber B. F., Moellering R. C., Jr Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983 Jan;23(1):138–141. doi: 10.1128/aac.23.1.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fee W. E., Jr, Vierra V., Lathrop G. R. Clinical evaluation of aminoglycoside toxicity: tobramycin versus gentamicin, a preliminary report. J Antimicrob Chemother. 1978 May;4 (Suppl A):31–36. doi: 10.1093/jac/4.suppl_a.31. [DOI] [PubMed] [Google Scholar]
  17. GERACI J. E., HEILMAN F. R., NICHOLS D. R., WELLMAN W. E. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report. Proc Staff Meet Mayo Clin. 1958 Apr 2;33(7):172–181. [PubMed] [Google Scholar]
  18. Geraci J. E. Vancomycin. Mayo Clin Proc. 1977 Oct;52(10):631–634. [PubMed] [Google Scholar]
  19. Griffith R. S. Introduction to vancomycin. Rev Infect Dis. 1981 Nov-Dec;3 Suppl:S200–S204. [PubMed] [Google Scholar]
  20. Guerit J. M., Mahieu P., Houben-Giurgea S., Herbay S. The influence of ototoxic drugs on brainstem auditory evoked potentials in man. Arch Otorhinolaryngol. 1981;233(2):189–199. doi: 10.1007/BF00453643. [DOI] [PubMed] [Google Scholar]
  21. Hall J. W., 3rd, Brown D. P., Mackey-Hargadine J. R. Pediatric applications of serial auditory brainstem and middle-latency evoked response recordings. Int J Pediatr Otorhinolaryngol. 1985 Aug;9(3):201–218. doi: 10.1016/s0165-5876(85)80036-7. [DOI] [PubMed] [Google Scholar]
  22. Hall J. W., 3rd, Herndon D. N., Gary L. B., Winkler J. B. Auditory brainstem response in young burn-wound patients treated with ototoxic drugs. Int J Pediatr Otorhinolaryngol. 1986 Dec;12(2):187–203. doi: 10.1016/s0165-5876(86)80075-1. [DOI] [PubMed] [Google Scholar]
  23. Haydon R. C., Thelin J. W., Davis W. E. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg. 1984 Dec;92(6):678–684. doi: 10.1177/019459988409200615. [DOI] [PubMed] [Google Scholar]
  24. Hook E. W., 3rd, Johnson W. D., Jr Vancomycin therapy of bacterial endocarditis. Am J Med. 1978 Sep;65(3):411–415. doi: 10.1016/0002-9343(78)90766-0. [DOI] [PubMed] [Google Scholar]
  25. Hugues F. C., Laccourreye A., Lasserre M. H., Toupet M. Recherche d'une toxicité cochléaire de l'érythromycine chez le malade âgé. Therapie. 1984 Sep-Oct;39(5):591–594. [PubMed] [Google Scholar]
  26. Johnson A. H., Hamilton C. H. Kanamycin ototoxicity--possible potentiation by other drugs. South Med J. 1970 May;63(5):511–513. doi: 10.1097/00007611-197005000-00007. [DOI] [PubMed] [Google Scholar]
  27. KIRBY W. M., PERRY D. M., BAUER A. W. Treatment of staphylococcal septicemia with vancomycin: report of thirty-three cases. N Engl J Med. 1960 Jan 14;262:49–55. doi: 10.1056/NEJM196001142620201. [DOI] [PubMed] [Google Scholar]
  28. Kanfer A., Daniel F., Vigeral P., Méry J. P., Haguet J. F. Surdité transitoire chez des insuffisants rénaux traités par l'érythromycine. Nouv Presse Med. 1979 Jun 16;8(27):2283–2284. [PubMed] [Google Scholar]
  29. Kanfer A., Daniel F., Vigeral P., Méry J. P. Oto-toxicité de l'érythromycine au cours de l'insuffisance rénale chronique. Therapie. 1980 May-Jun;35(3):365–367. [PubMed] [Google Scholar]
  30. Karmody C. S., Weinstein L. Reversible sensorineural hearing loss with intravenous erythromycin lactobionate. Ann Otol Rhinol Laryngol. 1977 Jan-Feb;86(1 Pt 1):9–11. doi: 10.1177/000348947708600103. [DOI] [PubMed] [Google Scholar]
  31. Koegel L., Jr Ototoxicity: a contemporary review of aminoglycosides, loop diuretics, acetylsalicylic acid, quinine, erythromycin, and cisplatinum. Am J Otol. 1985 Mar;6(2):190–199. [PubMed] [Google Scholar]
  32. Kroboth P. D., McNeil M. A., Kreeger A., Dominguez J., Rault R. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis. Arch Intern Med. 1983 Jun;143(6):1263–1265. [PubMed] [Google Scholar]
  33. Lackner T. E. Relationship of vancomycin concentrations and ototoxicity. Arch Intern Med. 1984 Feb;144(2):419–419. [PubMed] [Google Scholar]
  34. Levin G., Behrenth E. Irreversible ototoxic effect of erythromycin. Scand Audiol. 1986;15(1):41–42. doi: 10.3109/01050398609045952. [DOI] [PubMed] [Google Scholar]
  35. Lornoy W., Steyaert J. Ototoxicity of erythromycin lactobionate. Acta Clin Belg. 1979;34(2):111–111. doi: 10.1080/22953337.1979.11718674. [DOI] [PubMed] [Google Scholar]
  36. Masur H., Francioli P., Ruddy M., Murray H. W. Vancomycin serum levels and toxicity in chronic hemodialysis patients with Staphylococcus aureus bacteremia. Clin Nephrol. 1983 Aug;20(2):85–88. [PubMed] [Google Scholar]
  37. Matz G. J. Aminoglycoside ototoxicity. Am J Otolaryngol. 1986 Mar-Apr;7(2):117–119. doi: 10.1016/s0196-0709(86)80040-0. [DOI] [PubMed] [Google Scholar]
  38. Matz G. J., Lerner S. A., Lanzl E. F. Aminoglycoside antibiotics in the treatment of otologic infections. Otolaryngol Head Neck Surg. 1981 Sep-Oct;89(5):705–709. doi: 10.1177/019459988108900501. [DOI] [PubMed] [Google Scholar]
  39. Mellor J. A., Kingdom J., Cafferkey M., Keane C. T. Vancomycin toxicity: a prospective study. J Antimicrob Chemother. 1985 Jun;15(6):773–780. doi: 10.1093/jac/15.6.773. [DOI] [PubMed] [Google Scholar]
  40. Mellor J. A., Kingdom J., Cafferkey M., Keane C. Vancomycin ototoxicity in patients with normal renal function. Br J Audiol. 1984 Aug;18(3):179–180. doi: 10.3109/03005368409078946. [DOI] [PubMed] [Google Scholar]
  41. Meyer R. D., Edelstein P. H., Kirby B. D., Louie M. H., Mulligan M. E., Morgenstein A. A., Finegold S. M. Legionnaires' disease: unusual clinical and laboratory features. Ann Intern Med. 1980 Aug;93(2):240–243. doi: 10.7326/0003-4819-93-2-240. [DOI] [PubMed] [Google Scholar]
  42. Miller S. M. Erythromycin ototoxicity. Med J Aust. 1982 Sep 4;2(5):242–243. [PubMed] [Google Scholar]
  43. Mintz U., Amir J., Pinkhas J., de Vries A. Transient perceptive deafness due to erythromycin lactobionate. JAMA. 1973 Aug 27;225(9):1122–1123. doi: 10.1001/jama.1973.03220370060028. [DOI] [PubMed] [Google Scholar]
  44. Morris A. J., Bilinsky R. T. Prevention of staphylococcal shunt infections by continuous vancomycin prophylaxis. Am J Med Sci. 1971 Aug;262(2):87–92. doi: 10.1097/00000441-197108000-00003. [DOI] [PubMed] [Google Scholar]
  45. Méry J. P., Kanfer A. Erythromycin-induced ototoxicity. Mayo Clin Proc. 1983 Jun;58(6):401–401. [PubMed] [Google Scholar]
  46. Méry J. P., Kanfer A. Ototoxicity of erythromycin in patients with renal insufficiency. N Engl J Med. 1979 Oct 25;301(17):944–944. doi: 10.1056/nejm197910253011716. [DOI] [PubMed] [Google Scholar]
  47. Nishioka K., Masuda Y., Okada S., Takata N., Tasaka S., Ogura Y. Bilateral sensorineural hearing loss associated with Mycoplasma pneumoniae infection. Laryngoscope. 1987 Oct;97(10):1203–1206. doi: 10.1288/00005537-198710000-00015. [DOI] [PubMed] [Google Scholar]
  48. Pfeiffer R. R. Structural features of vancomycin. Rev Infect Dis. 1981 Nov-Dec;3 Suppl:S205–S209. [PubMed] [Google Scholar]
  49. Quinnan G. V., Jr, McCabe W. R. Ototoxicity of erythromycin. Lancet. 1978 May 27;1(8074):1160–1161. doi: 10.1016/s0140-6736(78)90344-6. [DOI] [PubMed] [Google Scholar]
  50. ROTHENBERG H. J. Anaphylactoid reaction to vancomycin. J Am Med Assoc. 1959 Oct 24;171:1101–1102. doi: 10.1001/jama.1959.73010260008010b. [DOI] [PubMed] [Google Scholar]
  51. Rydberg J. Reversibel hörselnedsättning och erytromycin. Lakartidningen. 1984 Mar 28;81(13):1308–1308. [PubMed] [Google Scholar]
  52. Schwartz J. I., Maggini G. A. Erythromycin-induced ototoxicity substantiated by rechallenge. Clin Pharm. 1982 Jul-Aug;1(4):374–376. [PubMed] [Google Scholar]
  53. Schweitzer V. G., Olson N. R. Ototoxic effect of erythromycin therapy. Arch Otolaryngol. 1984 Apr;110(4):258–260. doi: 10.1001/archotol.1984.00800300050011. [DOI] [PubMed] [Google Scholar]
  54. Sorrell T. C., Collignon P. J. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother. 1985 Aug;16(2):235–241. doi: 10.1093/jac/16.2.235. [DOI] [PubMed] [Google Scholar]
  55. Stupp H., Küpper K., Lagler F., Sous H., Quante M. Inner ear concentrations and ototoxicity of different antibiotics in local and systemic application. Audiology. 1973 Sep-Dec;12(5):350–363. doi: 10.3109/00206097309071650. [DOI] [PubMed] [Google Scholar]
  56. Taylor R., Schofield I. S., Ramos J. M., Bint A. J., Ward M. K. Ototoxicity of erythromycin in peritoneal dialysis patients. Lancet. 1981 Oct 24;2(8252):935–936. [PubMed] [Google Scholar]
  57. Thompson P., Wood R. P., 2nd, Bergstrom L. Erythromycin ototoxicity. J Otolaryngol. 1980 Feb;9(1):60–62. [PubMed] [Google Scholar]
  58. Traber P. G., Levine D. P. Vancomycin Ototoxicity in patient with normal renal function. Ann Intern Med. 1981 Oct;95(4):458–460. doi: 10.7326/0003-4819-95-4-458. [DOI] [PubMed] [Google Scholar]
  59. Umstead G. S., Neumann K. H. Erythromycin ototoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction. Arch Intern Med. 1986 May;146(5):897–899. [PubMed] [Google Scholar]
  60. WOODLEY D. W., HALL W. H. The treatment of severe staphylococcal infections with vancomycin. Ann Intern Med. 1961 Aug;55:235–249. doi: 10.7326/0003-4819-55-2-235. [DOI] [PubMed] [Google Scholar]
  61. Wood C. A., Kohlhepp S. J., Kohnen P. W., Houghton D. C., Gilbert D. N. Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother. 1986 Jul;30(1):20–24. doi: 10.1128/aac.30.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. van Marion W. F., van der Meer J. W., Kalff M. W., Schicht S. M. Ototoxicity of erythromycin. Lancet. 1978 Jul 22;2(8082):214–215. doi: 10.1016/s0140-6736(78)91961-x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES